NA
EW icon

Navellier & Associates’s Edwards Lifesciences EW Stock Holding History

Navellier & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-135,582
Closed -$4.24M – 287
2016
Q4 		$4.24M Sell
135,582
-161,736
-54% -$5.24M 0.7% 59
2016
Q3 		$11.9M Buy
297,318
+167,178
+128% +$6.3M 1.71% 8
2016
Q2 		$4.33M Buy
130,140
+40,938
+46% +$1.4M 0.65% 49
2016
Q1 		$2.62M Buy
89,202
+37,317
+72% +$1.03M 0.34% 55
2015
Q4 		$1.37M Sell
51,885
-5,055
-9% -$131K 0.15% 66
2015
Q3 		$1.35M Sell
56,940
-96
-0.2% -$2.32K 0.14% 74
2015
Q2 		$1.35M Buy
57,036
+12,948
+29% +$292K 0.12% 96
2015
Q1 		$1.05M Buy
44,088
+11,370
+35% +$255K 0.09% 109
2014
Q4 		$695K Buy
+32,718
New +$657K 0.03% 146

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Navellier & Associates's EW Position: Q1 2017 in Review

Navellier & Associates sold out of Edwards Lifesciences (EW) in Q1 2017, closing a stake of 135,582 shares — an estimated $4.24M sold.

Navellier & Associates first reported a position in EW in Q4 2014 and held it in 9 quarters. The position peaked at $11.9M in Q3 2016. 691 funds tracked by Wall St. Rank hold EW as of Q1 2017.

  • Navellier & Associates reported no remaining Edwards Lifesciences position as of Q1 2017 after selling out during the quarter.
  • Navellier & Associates sold 135,582 Edwards Lifesciences shares in Q1 2017, an estimated $4.24M.
  • Navellier & Associates first reported a position in Edwards Lifesciences in Q4 2014 and held it in 9 quarters.
  • Navellier & Associates's Edwards Lifesciences position peaked at $11.9M in Q3 2016.
  • 691 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2017.

Based on Navellier & Associates's 13F filing for Q1 2017, filed 21 Apr 2017.